The management of side-effects during therapy for hepatitis C.
about
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrenceComparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.Management of Hepatitis C Antiviral Therapy Adverse Effects.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Chronic hepatitis C virus management: 2000-2005 update.Improving anti-hepatitis C virus therapy.The role of the community nurse in hepatitis C diagnosis and treatment.Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study.Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response.Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India.Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.Risk of autoimmune complications associated with interferon therapy.Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence.
P2860
Q27490405-857F19E3-57F0-4B91-826D-C093A3CA6648Q34365412-A491ABAA-C8EF-4402-8FB5-6B7E4A00A875Q34538771-D4D626BA-7A79-4718-8BC5-D3AEDD1F37C8Q34996746-3AD26989-EC37-494B-866B-145FCBB79C13Q36348376-A4025FA2-FA60-42D2-AE4C-FE169C36335EQ36569749-4EBE61B6-5E75-42CE-88A8-AE63B9086223Q37549859-2FE15C0A-52F9-4ED0-AB69-DCFE0B95A4ABQ37688134-3331CE51-B524-45E9-8F0B-2C906A470915Q38621703-4A832598-30A3-4623-8A83-F7A118313FE1Q39507721-756F3294-1866-47F0-9692-CA508FD5C3F6Q40108841-D577D939-B55F-4F89-AA95-4147CCCA1F22Q42232204-A6F28EEF-DE90-44EF-97D1-F4253C4D9D07Q42245471-2B0CEDC2-F016-42AA-A919-188BBE933EFEQ42435536-097E36EE-33AB-4943-A5EE-A741AEEB3EFFQ42725859-C0954B4E-6FEF-4529-9DD4-A36318C65B9A
P2860
The management of side-effects during therapy for hepatitis C.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The management of side-effects during therapy for hepatitis C.
@ast
The management of side-effects during therapy for hepatitis C.
@en
type
label
The management of side-effects during therapy for hepatitis C.
@ast
The management of side-effects during therapy for hepatitis C.
@en
prefLabel
The management of side-effects during therapy for hepatitis C.
@ast
The management of side-effects during therapy for hepatitis C.
@en
P2860
P1476
The management of side-effects during therapy for hepatitis C.
@en
P2093
P J Pockros
R J Aspinall
P2860
P304
P356
10.1111/J.1365-2036.2004.02192.X
P407
P577
2004-11-01T00:00:00Z